AAVantgarde and TIGEM Achieve Breakthrough in Gene Therapy for Stargardt’s Disease

AAVantgarde Bio, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), has published a breakthrough study on gene therapy for Stargardt’s disease in the prestigious journal Science Advances. The research highlights the potential of AAVantgarde’s proprietary AAV intein platform, demonstrating both safety and efficacy in large animal models. This milestone strengthens the foundation for translating the therapy into clinical trials, offering new hope for patients with this progressive retinal disorder.

Dr. Natalia Misciattelli, CEO of AAVantgarde, emphasized that this collaboration with TIGEM is pushing the boundaries of gene therapy, bringing them closer to a transformative treatment. Professor Alberto Auricchio, CSO of AAVantgarde and Scientific Director at TIGEM, added that the study exemplifies how advanced vector engineering and deep biological insights can pave the way for innovative genetic therapies. With these promising findings, AAVantgarde and TIGEM are poised to take a crucial step toward clinical applications, potentially changing the landscape for patients suffering from Stargardt’s disease.